What is Monogram Orthopaedics Inc's earnings per share (EPS)?

Monogram Orthopaedics Inc (MGRM) reported diluted earnings per share of $-0.51 for fiscal year 2024. This represents a 16.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Monogram Orthopaedics Inc Financials

MGRM

Source SEC Filings (10-K/10-Q) Updated Jun 30, 2025 Currency USD FYE December

This page shows Monogram Orthopaedics Inc (MGRM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Monogram Orthopaedics Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.86x

For every $1 of reported earnings, Monogram Orthopaedics Inc generates $0.86 in operating cash flow (-$14.0M OCF vs -$16.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$14.9M

YoY+11.7%

Monogram Orthopaedics Inc's EBITDA was -$14.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 11.7% from the prior year.

Net Income

-$16.3M

YoY-18.8%

Monogram Orthopaedics Inc reported -$16.3M in net income in fiscal year 2024. This represents a decrease of 18.8% from the prior year.

EPS (Diluted)

$-0.51

YoY+16.4%

Monogram Orthopaedics Inc earned $-0.51 per diluted share (EPS) in fiscal year 2024. This represents an increase of 16.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$15.7M

YoY+15.2%

Monogram Orthopaedics Inc held $15.7M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

35M

YoY+12.2%

Monogram Orthopaedics Inc had 35M shares outstanding in fiscal year 2024. This represents an increase of 12.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-112.6%

YoY-10.0pp

Monogram Orthopaedics Inc's ROE was -112.6% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 10.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$8.8M

YoY-17.0%

Monogram Orthopaedics Inc invested $8.8M in research and development in fiscal year 2024. This represents a decrease of 17.0% from the prior year.

Share Buybacks

$200K

Monogram Orthopaedics Inc spent $200K on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

N/A

MGRM Income Statement

Metric	FY24	FY23	FY22
Revenue	N/A	$365K	N/A
Cost of Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
R&D Expenses	$8.8M-17.0%	$10.6M+96.6%	$5.4M
SG&A Expenses	$4.4M+8.9%	$4.1M+63.1%	$2.5M
Operating Income	-$15.3M+11.3%	-$17.3M-62.7%	-$10.6M
Interest Expense	N/A	N/A	N/A
Income Tax	$0	$0	$0
Net Income	-$16.3M-18.8%	-$13.7M-0.4%	-$13.7M
EPS (Diluted)	$-0.51+16.4%	$-0.61	$-1.42

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.3M0.0%	$2.3M	N/A	$2.2M-8.7%	$2.4M+0.8%	$2.4M	N/A	$2.7M
SG&A Expenses	$772K-25.2%	$1.0M	N/A	$1.1M-2.0%	$1.1M+3.0%	$1.1M	N/A	$1.1M
Operating Income	-$3.1M+7.9%	-$3.3M	N/A	-$5.1M-41.6%	-$3.6M-0.7%	-$3.6M	N/A	-$3.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$5.4M-70.7%	-$3.2M	N/A	-$5.0M-42.3%	-$3.5M-0.9%	-$3.5M	N/A	-$996K
EPS (Diluted)	$-0.16-60.0%	$-0.10	N/A	$-0.16-45.5%	$-0.110.0%	$-0.11	N/A	$-0.03

MGRM Balance Sheet

Metric	FY24	FY23	FY22
Total Assets	$17.8M+7.2%	$16.6M+21.1%	$13.7M
Current Assets	$16.3M+11.4%	$14.6M+29.9%	$11.3M
Cash & Equivalents	$15.7M+15.2%	$13.6M+29.8%	$10.5M
Inventory	N/A	$5K0.0%	$5K
Accounts Receivable	N/A	$365K	N/A
Goodwill	N/A	N/A	N/A
Total Liabilities	$3.3M+2.6%	$3.2M-66.6%	$9.5M
Current Liabilities	$1.5M-45.3%	$2.8M-68.8%	$9.0M
Long-Term Debt	N/A	N/A	N/A
Total Equity	$14.5M+8.3%	$13.4M+222.9%	$4.1M
Retained Earnings	-$68.0M-32.0%	-$51.5M-36.4%	-$37.8M

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$15.0M-2.3%	$15.4M-13.6%	$17.8M-12.1%	$20.2M+106.0%	$9.8M-21.7%	$12.5M-24.4%	$16.6M-9.1%	$18.2M
Current Assets	$13.5M-2.9%	$13.9M-14.9%	$16.3M-12.6%	$18.6M+129.4%	$8.1M-24.2%	$10.7M-26.8%	$14.6M-9.6%	$16.2M
Cash & Equivalents	$12.8M-3.3%	$13.3M-15.3%	$15.7M-5.5%	$16.6M+126.7%	$7.3M-27.5%	$10.1M-25.8%	$13.6M-8.6%	$14.9M
Inventory	N/A	N/A	N/A	$290K-2.5%	$298K	N/A	$5K0.0%	$5K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	$365K	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.4M+74.0%	$3.7M+12.3%	$3.3M+16.3%	$2.8M+1.2%	$2.8M+19.9%	$2.3M-27.3%	$3.2M-50.0%	$6.4M
Current Liabilities	$6.2M+214.9%	$2.0M+28.4%	$1.5M-39.5%	$2.5M+2.8%	$2.5M+25.0%	$2.0M-29.6%	$2.8M-52.7%	$6.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.6M-26.3%	$11.7M-19.4%	$14.5M-16.7%	$17.4M+147.3%	$7.0M-31.1%	$10.2M-23.7%	$13.4M+12.8%	$11.9M
Retained Earnings	-$77.0M-7.9%	-$71.4M-5.0%	-$68.0M-6.7%	-$63.7M-8.8%	-$58.6M-6.4%	-$55.0M-6.8%	-$51.5M-7.6%	-$47.9M

MGRM Cash Flow Statement

Metric	FY24	FY23	FY22
Operating Cash Flow	-$14.0M-3.1%	-$13.5M-60.9%	-$8.4M
Capital Expenditures	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A
Investing Cash Flow	-$84K-29.2%	-$65K+73.1%	-$241K
Financing Cash Flow	$16.1M-3.6%	$16.7M+23.1%	$13.6M
Dividends Paid	$151K	N/A	N/A
Share Buybacks	$200K	N/A	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$2.3M+0.7%	-$2.3M+22.9%	-$3.0M+33.2%	-$4.5M-58.8%	-$2.8M+22.6%	-$3.7M-17.3%	-$3.1M-87.3%	-$1.7M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$218K-39.7%	-$156K-331.0%	-$36K+1.7%	-$37K	$0+100.0%	-$11K+54.6%	-$24K-622.1%	-$3K
Financing Cash Flow	$2.1M+2435.4%	$82K-96.1%	$2.1M-84.5%	$13.8M+24963.9%	$55K-63.6%	$151K-91.8%	$1.9M+432.2%	-$557K
Dividends Paid	N/A	N/A	N/A	$121K	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

MGRM Financial Ratios

Metric	FY24	FY23	FY22
Gross Margin	N/A	N/A	N/A
Operating Margin	N/A	-4731.0%	N/A
Net Margin	N/A	-3765.8%	N/A
Return on Equity	-112.6%-10.0pp	-102.6%+227.4pp	-330.0%
Return on Assets	-91.9%-9.0pp	-82.9%+17.1pp	-100.0%
Current Ratio	10.57+5.4	5.19+3.9	1.24
Debt-to-Equity	0.23-0.0	0.24-2.1	2.30
FCF Margin	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-63.1%-35.9pp	-27.3%	N/A	-28.9%+21.3pp	-50.2%-15.9pp	-34.3%	N/A	-8.4%
Return on Assets	-36.3%-15.5pp	-20.8%	N/A	-24.9%+11.1pp	-36.0%-8.1pp	-28.0%	N/A	-5.5%
Current Ratio	2.16-4.8	7.00-3.6	10.57+3.3	7.31+4.0	3.28-2.1	5.40+0.2	5.19+2.5	2.71
Debt-to-Equity	0.74+0.4	0.31+0.1	0.23+0.1	0.16-0.2	0.39+0.2	0.23-0.0	0.24-0.3	0.54
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Quantum-Si Incorporated QSI

$161.8M

TriSalus Life Sciences Inc. TLSI

$260.4M

Inogen Inc INGN

$169.1M

Quanterix QTRX

$177.9M

BioSig Technologies Inc BSGM

$157.0M

Frequently Asked Questions

Is Monogram Orthopaedics Inc profitable?

No, Monogram Orthopaedics Inc (MGRM) reported a net income of -$16.3M in fiscal year 2024.

What is Monogram Orthopaedics Inc's EBITDA?

Monogram Orthopaedics Inc (MGRM) had EBITDA of -$14.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Monogram Orthopaedics Inc's return on equity (ROE)?

Monogram Orthopaedics Inc (MGRM) has a return on equity of -112.6% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Monogram Orthopaedics Inc's operating cash flow?

Monogram Orthopaedics Inc (MGRM) generated -$14.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Monogram Orthopaedics Inc's total assets?

Monogram Orthopaedics Inc (MGRM) had $17.8M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Monogram Orthopaedics Inc spend on research and development?

Monogram Orthopaedics Inc (MGRM) invested $8.8M in research and development during fiscal year 2024.

Does Monogram Orthopaedics Inc buy back shares?

Yes, Monogram Orthopaedics Inc (MGRM) spent $200K on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.

How many shares does Monogram Orthopaedics Inc have outstanding?

Monogram Orthopaedics Inc (MGRM) had 35M shares outstanding as of fiscal year 2024.

What is Monogram Orthopaedics Inc's current ratio?

Monogram Orthopaedics Inc (MGRM) had a current ratio of 10.57 as of fiscal year 2024, which is generally considered healthy.

What is Monogram Orthopaedics Inc's debt-to-equity ratio?

Monogram Orthopaedics Inc (MGRM) had a debt-to-equity ratio of 0.23 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Monogram Orthopaedics Inc's return on assets (ROA)?

Monogram Orthopaedics Inc (MGRM) had a return on assets of -91.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Monogram Orthopaedics Inc's cash runway?

Based on fiscal year 2024 data, Monogram Orthopaedics Inc (MGRM) had $15.7M in cash against an annual operating cash burn of $14.0M. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Monogram Orthopaedics Inc's Piotroski F-Score?

Monogram Orthopaedics Inc (MGRM) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Monogram Orthopaedics Inc's earnings high quality?

Monogram Orthopaedics Inc (MGRM) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.